<DOC>
	<DOCNO>NCT00000525</DOCNO>
	<brief_summary>To determine whether hypertensive patient ECG abnormality receive hydrochlorothiazide diuretic increase risk sudden death .</brief_summary>
	<brief_title>Diuretics , Hypertension , Arrhythmias Clinical Trial</brief_title>
	<detailed_description>BACKGROUND : The Multiple Risk Factor Intervention Trial ( MRFIT ) reveal unexpected subgroup finding : association diuretic therapy ( especially hydrochlorothiazide ) increase rate sudden death hypertensive men leave ventricular hypertrophy ECG abnormality . The Diuretics , Hypertension , Arrhythmias Clinical Trial seek determine whether find result random variation represent serious toxic response hydrochlorothiazide . DESIGN NARRATIVE : Randomized , double-blind . Following one month withdrawal diuretic repletion oral potassium magnesium , study participant randomize two month treatment one six treatment group : hydrochlorothiazide ; hydrochlorothiazide oral potassium ; hydrochlorothiazide oral potassium magnesium ; hydrochlorothiazide triamterene ; chlorthalidone ; placebo . The main outcome measure ventricular arrhythmia 24-hour Holter monitoring serum intracellular potassium magnesium level .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Heart Arrest</mesh_term>
	<mesh_term>Death , Sudden</mesh_term>
	<mesh_term>Death , Sudden , Cardiac</mesh_term>
	<mesh_term>Chlorthalidone</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Triamterene</mesh_term>
	<criteria>Men , age 35 70 , ECG abnormality , diastolic blood pressure le 95 mm Hg entry . Subjects treat least six month physician hydrochlorothiazide ( HCT ) , HCT potassium supplementation , triamteren</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>